|
1
|
You Y, Li H, Chen J, Qin X and Ran Y:
Zoledronic acid reverses cisplatin resistance in nasopharyngeal
carcinoma cells by activating the mitochondrial apoptotic pathway.
Oncol Lett. 13:1840–1846. 2017.PubMed/NCBI
|
|
2
|
Minsky BD, Pajak TF, Ginsberg RJ, Pisansky
TM, Martenson J, Komaki R, Okawara G, Rosenthal SA and Kelsen DP:
INT 0123 (radiation therapy oncology group 94-05) phase III trial
of combined-modality therapy for esophageal cancer: High-dose
versus standard-dose radiation therapy. J Clin Oncol. 20:1167–1174.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yamashita S, Kondo M and Hashimoto S:
Squamous cell carcinoma of the nasopharynx. An analysis of failure
patterns after radiation therapy. Acta Radiol Oncol. 24:315–320.
1985. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Al-Sarraf M, LeBlanc M, Giri PG, Fu KK,
Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE and
Ensley JF: Chemoradiotherapy versus radiotherapy in patients with
advanced nasopharyngeal cancer: Phase III randomized Intergroup
study 0099. J Clin Oncol. 16:1310–1317. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mao YP, Zhou GQ, Liu LZ, Guo R, Sun Y, Li
L, Lin AH, Zeng MS, Kang TB, Jia WH, et al: Comparison of
radiological and clinical features of temporal lobe necrosis in
nasopharyngeal carcinoma patients treated with 2D radiotherapy or
intensity-modulated radiotherapy. Br J Cancer. 110:2633–2639. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jemal A, Murray T, Ward E, Samuels A,
Tiwari RC, Ghafoor A, Feuer EJ and Thun MJ: Cancer statistics,
2005. CA Cancer J Clin. 55:10–30. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dunford JE, Thompson K, Coxon FP, Luckman
SP, Hahn FM, Poulter CD, Ebetino FH and Rogers MJ:
Structure-activity relationships for inhibition of farnesyl
diphosphate synthase in vitro and inhibition of bone resorption in
vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther.
296:235–242. 2001.PubMed/NCBI
|
|
8
|
Yuasa T, Kimura S, Ashihara E, Habuchi T
and Maekawa T: Zoledronic acid - a multiplicity of anti-cancer
action. Curr Med Chem. 14:2126–2135. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jantunen E: Bisphosphonate therapy in
multiple myeloma: Past, present, future. Eur J Haematol.
69:257–264. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Koto K, Murata H, Kimura S, Horie N,
Matsui T, Nishigaki Y, Ryu K, Sakabe T, Itoi M, Ashihara E, et al:
Zoledronic acid inhibits proliferation of human fibrosarcoma cells
with induction of apoptosis, and shows combined effects with other
anticancer agents. Oncol Rep. 24:233–239. 2010.PubMed/NCBI
|
|
11
|
Zhao M, Tominaga Y, Ohuchida K, Mizumoto
K, Cui L, Kozono S, Fujita H, Maeyama R, Toma H and Tanaka M:
Significance of combination therapy of zoledronic acid and
gemcitabine on pancreatic cancer. Cancer Sci. 103:58–66. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Matsumoto S, Kimura S, Segawa H, Kuroda J,
Yuasa T, Sato K, Nogawa M, Tanaka F, Maekawa T and Wada H: Efficacy
of the third-generation bisphosphonate, zoledronic acid alone and
combined with anti-cancer agents against small cell lung cancer
cell lines. Lung Cancer. 47:31–39. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ge XY, Yang LQ, Jiang Y, Yang WW, Fu J and
Li SL: Reactive oxygen species and autophagy associated apoptosis
and limitation of clonogenic survival induced by zoledronic acid in
salivary adenoid cystic carcinoma cell line SACC-83. PLoS One.
9:e1012072014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Di Salvatore M, Orlandi A, Bagalà C,
Quirino M, Cassano A, Astone A and Barone C: Anti-tumour and
anti-angiogenetic effects of zoledronic acid on human
non-small-cell lung cancer cell line. Cell Prolif. 44:139–146.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
You Y, Liu J, Wang Z, Zhang Y, Ran Y, Guo
X, Liu H and Wang H: The enhancement of radiosensitivity in human
esophageal squamous cell carcinoma cells by zoledronic acid and its
potential mechanism. Cytotechnology. 66:17–25. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Algur E, Macklis RM and Häfeli UO:
Synergistic cytotoxic effects of zoledronic acid and radiation in
human prostate cancer and myeloma cell lines. Int J Radiat Oncol
Biol Phys. 61:535–542. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ryu K, Murata H, Koto K, Horie N, Matsui
T, Nishigaki Y, Sakabe T, Takeshita H, Itoi M, Kimura S, et al:
Combined effects of bisphosphonate and radiation on osteosarcoma
cells. Anticancer Res. 30:2713–2720. 2010.PubMed/NCBI
|
|
18
|
Lopez Jornet P, Susana SC, Rosario TM and
Alvaro PF: Zoledronic acid and irradiation in oral squamous cell
carcinoma. J Oral Pathol Med. 44:103–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ural AU and Avcu F: Radiosensitizing
effect of zoledronic acid in small cell lung cancer. Lung Cancer.
50:271–272. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ural AU, Avcu F, Candir M, Guden M and
Ozcan MA: In vitro synergistic cytoreductive effects of zoledronic
acid and radiation on breast cancer cells. Breast Cancer Res.
8:R522006. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
You Y, Yang W, Qin X, Wang F, Li H, Lin C,
Li W, Gu C, Zhang Y and Ran Y: ECRG4 acts as a tumor suppressor and
as a determinant of chemotherapy resistance in human nasopharyngeal
carcinoma. Cell Oncol (Dordr). 38:205–214. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chan SY, Choy KW, Tsao SW, Tao Q, Tang T,
Chung GT and Lo KW: Authentication of nasopharyngeal carcinoma
tumor lines. Int J Cancer. 122:2169–2171. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ye F, Chen C, Qin J, Liu J and Zheng C:
Genetic profiling reveals an alarming rate of cross-contamination
among human cell lines used in China. FASEB J. 29:4268–4272. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
You Y, Yang W, Wang Z, Zhu H, Li H, Lin C
and Ran Y: Promoter hypermethylation contributes to the frequent
suppression of the CDK10 gene in human nasopharyngeal carcinomas.
Cell Oncol (Dordr). 36:323–331. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kuroda J, Kimura S, Segawa H, Sato K,
Matsumoto S, Nogawa M, Yuasa T, Kobayashi Y, Yoshikawa T, Ottmann
OG and Maekawa T: p53-independent anti-tumor effects of the
nitrogen-containing bisphosphonate zoledronic acid. Cancer Sci.
95:186–192. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li YY, Chang JW, Liu YC, Wang CH, Chang
HJ, Tsai MC, Su SP and Yeh KY: Zoledronic acid induces cell-cycle
prolongation in murine lung cancer cells by perturbing cyclin and
Ras expression. Anticancer Drugs. 22:89–98. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mani J, Vallo S, Barth K, Makarević J,
Juengel E, Bartsch G, Wiesner C, Haferkamp A and Blaheta RA:
Zoledronic acid influences growth, migration and invasive activity
of prostate cancer cells in vitro. Prostate Cancer Prostatic Dis.
15:250–255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li XY, Lin Y, Huang W, Hong CQ, Chen JY,
You YJ and Li WB: Zoledronic acid inhibits proliferation and
impairs migration and invasion through downregulating VEGF and MMPs
expression in human nasopharyngeal carcinoma cells. Med Oncol.
29:714–720. 2013. View Article : Google Scholar
|
|
29
|
Skerjanec A, Berenson J, Hsu C, Major P,
Miller WH Jr, Ravera C, Schran H, Seaman J and Waldmeier F: The
pharmacokinetics and pharmacodynamics of zoledronic acid in cancer
patients with varying degrees of renal function. J Clin Pharmacol.
43:154–162. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sinclair WK: Cyclic x-ray responses in
mammalian cells in vitro. Radiat Res. 33:620–643. 1968. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Milas L, Hunter NR, Mason KA, Kurdoglu B
and Peters LJ: Enhancement of tumor radioresponse of a murine
mammary carcinoma by paclitaxel. Cancer Res. 54:3506–3510.
1994.PubMed/NCBI
|
|
32
|
Yip KW, Shi W, Pintilie M, Martin JD,
Mocanu JD, Wong D, MacMillan C, Gullane P, O'Sullivan B,
Bastianutto C and Liu FF: Prognostic significance of the
Epstein-Barr virus, p53, Bcl-2, and survivin in nasopharyngeal
cancer. Clin Cancer Res. 12:5726–5732. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ory B, Blanchard F, Battaglia S, Gouin F,
Rédini F and Heymann D: Zoledronic acid activates the DNA S-phase
checkpoint and induces osteosarcoma cell death characterized by
apoptosis-inducing factor and endonuclease-G translocation
independently of p53 and retinoblastoma status. Mol Pharmacol.
71:333–343. 2007. View Article : Google Scholar : PubMed/NCBI
|
